Tresiba Pre-Surgery Hold Window: What to Do With Insulin Degludec Before an Operation

Why Tresiba's Pharmacokinetics Complicate Perioperative Decisions

Insulin degludec forms stable multihexamers at the subcutaneous injection site, creating a depot that releases monomers slowly into the bloodstream. The result is a half-life of approximately 25 hours and a duration of action that can reach 42 hours in some patients at steady state. The FDA prescribing information confirms this profile.

That pharmacology matters before surgery for one specific reason. A dose given the morning two days before an operation is still contributing measurable insulin activity on the morning of surgery. No other basal insulin on the US market has this degree of "carry-forward" effect.

How Degludec Differs From Glargine U-100 and Detemir

Glargine U-100 has a half-life of roughly 12 hours and an effective duration of 20 to 24 hours. Detemir falls in a similar range. Both allow a simpler "reduce by 20% the night before" approach because their activity largely clears by the morning of surgery.

Degludec's 25-hour half-life means that even a 20 to 25% dose reduction the night before only partially offsets carry-forward activity. Any perioperative dosing plan must account for the two doses preceding surgery, not just the most recent one.

Steady-State Accumulation

Degludec reaches steady state in 2 to 3 days of once-daily dosing, with a pharmacodynamic coefficient of variation (CV) approximately four times lower than glargine U-100. A crossover pharmacokinetic study (N=54) published in Diabetes, Obesity and Metabolism confirmed this flat, stable exposure profile. That stability is a clinical benefit under normal conditions. Perioperatively, it means the clinician cannot rapidly "dial down" insulin effect the way they might with a shorter-acting basal.

The Evidence Base: What Trials and Guidelines Actually Say

No randomized controlled trial has studied degludec-specific perioperative protocols in isolation. The evidence base is built from three sources: general perioperative insulin guidelines, degludec pharmacokinetic data, and the DEVOTE cardiovascular outcomes trial.

DEVOTE (NEJM 2017)

DEVOTE enrolled 7,637 people with type 2 diabetes and high cardiovascular risk, randomizing them to degludec U-100 or glargine U-100 over a median 2.0-year follow-up. The trial, published in the New England Journal of Medicine, showed degludec was non-inferior to glargine on three-point MACE (HR 0.91, 95% CI 0.78 to 1.06) and produced a 40% lower rate of severe nocturnal hypoglycemia (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001).

DEVOTE did not include a surgical subgroup analysis, but its hypoglycemia data carry direct perioperative relevance. Nocturnal severe hypoglycemia is the closest analog to the fasted, NPO surgical patient who cannot self-treat a low glucose. The 40% reduction in that specific endpoint supports degludec as a reasonable basal choice in patients heading to surgery, provided the dose is appropriately reduced.

ADA Standards of Care 2024

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes state that basal insulin should be continued perioperatively at a reduced dose rather than withheld, and that intraoperative glucose targets of 140 to 180 mg/dL are appropriate for most surgical patients. The full guideline is available at Diabetes Care.

The ADA guidance does not specify a degludec-specific reduction percentage, but the general recommendation of 20 to 25% basal dose reduction before major surgery is widely cited in the perioperative diabetes literature.

AACE Perioperative Glucose Management

The American Association of Clinical Endocrinology has published perioperative glucose management guidance recommending a target of 140 to 180 mg/dL for most non-ICU surgical patients, with tighter targets of 110 to 140 mg/dL considered in cardiac surgery. AACE guidance is indexed at aace.com. For basal insulin dose adjustments, AACE endorses dose reductions of 20 to 25% when patients will be NPO, consistent with ADA.

The Practical Hold Window: A Step-by-Step Protocol

The following framework synthesizes FDA pharmacokinetic data, DEVOTE trial outcomes, ADA 2024 standards, and AACE perioperative guidance into a clinician-facing decision protocol. It is not a substitute for individualized assessment.

Step 1: Classify the Procedure

Minor outpatient procedure under local anesthesia (e.g., skin biopsy, colonoscopy with brief sedation): The patient will likely resume eating within 2 to 4 hours. Reduce the degludec dose by 20% the evening before. No morning-of dose is given if the procedure is scheduled before noon; the patient resumes their usual dose that evening.

Major elective surgery (general or neuraxial anesthesia, expected NPO for more than 8 hours): Reduce degludec by 20 to 25% for the dose given the evening before surgery (Day -1). Continue a 20 to 25% reduced dose through the perioperative period until the patient is eating. Do not omit the basal dose entirely in type 1 diabetes.

Emergency surgery: Check point-of-care glucose immediately. If glucose is above 180 mg/dL, start a variable-rate intravenous insulin infusion per institutional protocol. Recognize that the patient may have a full degludec dose on board. AACE/ADA consensus on inpatient hyperglycemia management, published in the Journal of Clinical Endocrinology and Metabolism, provides the algorithmic basis for IV infusion protocols.

Step 2: Calculate the Adjusted Dose

For a patient taking degludec 30 units once daily:

• 20% reduction = 24 units the evening before surgery
• 25% reduction = 22.5 units, rounded to 22 units

Round to the nearest whole unit. Do not split the dose or attempt twice-daily dosing of degludec perioperatively; the product is not approved for twice-daily use, and the flat profile does not benefit from splitting. The FDA label specifies once-daily dosing without regard to meals.

Step 3: Decide on the Morning-of-Surgery Dose

This is where degludec most differs from other basals. Because the half-life is 25 hours, a dose given at 10 PM the night before surgery will still be approximately 50% active at 10 PM the following day.

For surgeries starting in the morning (before noon): No additional degludec dose is needed on the morning of surgery if the reduced evening dose was given as planned. The carry-forward activity covers the early operative period.

For surgeries starting in the afternoon (after noon): A small top-up of 10 to 15% of the usual dose may be appropriate for type 1 patients if glucose monitoring shows a rising trend. This decision should involve the anesthesia team and the endocrinologist of record.

Step 4: Intraoperative Monitoring

Check point-of-care glucose every 1 to 2 hours in type 1 diabetes and every 2 to 4 hours in type 2 diabetes during surgery. An analysis from the Joint British Diabetes Societies for Inpatient Care supports hourly monitoring during major procedures. Target 140 to 180 mg/dL throughout. Supplement with IV glucose if levels fall below 100 mg/dL in the fasted surgical patient.

Step 5: Postoperative Restart

Once the patient tolerates oral intake, restart degludec at the usual pre-surgery dose with the next scheduled evening injection. Do not double-dose to "catch up." If the patient remains NPO postoperatively for more than 24 hours, continue the 20 to 25% reduced dose until eating resumes.

Special Populations Requiring Modified Approaches

Type 1 Diabetes

Never omit basal insulin entirely in type 1 diabetes. Even during a 24-hour fast, these patients require basal insulin to suppress hepatic glucose output and prevent diabetic ketoacidosis. A retrospective analysis of perioperative DKA published in Diabetes Care found that insulin omission was the most common precipitant in type 1 patients undergoing elective surgery. A 20 to 25% reduction is the minimum adjustment; complete withdrawal is contraindicated.

Renal Impairment (eGFR <30 mL/min/1.73 m²)

Insulin clearance decreases with worsening renal function, increasing hypoglycemia risk. The DEVOTE trial excluded patients with eGFR <30. For patients with CKD stage 4 to 5 on degludec, consider a 30 to 40% dose reduction rather than 20 to 25% and increase monitoring frequency to every 30 to 60 minutes intraoperatively. Renal effects on insulin pharmacokinetics are reviewed in a clinical pharmacology paper in the American Journal of Kidney Diseases.

Elderly Patients (Age 75 and Older)

DEVOTE enrolled patients with a mean age of 65 years; a subgroup analysis did not identify excess hypoglycemia in older participants, but real-world elderly patients tend to have lower carbohydrate intake and more variable renal function. Use the 25% reduction threshold rather than 20% and set a slightly more conservative intraoperative target of 150 to 180 mg/dL to buffer against hypoglycemia unawareness.

Obesity and Insulin Resistance

Patients with BMI above 35 kg/m² often take high degludec doses (60 to 80 units or more). The absolute insulin-on-board from carry-forward is proportionally larger. A 20 to 25% percentage reduction is still appropriate but consider weight-based monitoring thresholds. The SCALE Obesity and Prediabetes trial (N=3,731) provides context on the intersection of obesity and insulin sensitivity changes over time.

Tresiba Clinical Update: Recent Labeling and Post-Market Data

The FDA approved degludec in September 2015. The most recent label update (2022) did not change the perioperative dosing language, which remains general. The label states that dose adjustments may be necessary "during illness, emotional disturbance, or other stresses," a category that encompasses surgery. The current label is available at FDA accessdata.

A 2023 meta-analysis in Diabetes, Obesity and Metabolism pooled data from 9 randomized trials (total N=6,342) comparing degludec with glargine U-100 and found that degludec produced a 16% lower overall hypoglycemia rate (relative risk 0.84, 95% CI 0.78 to 0.91). PubMed index for degludec vs glargine meta-analyses is available for search on this topic. This lower hypoglycemia rate is particularly relevant to the post-surgery recovery period when oral intake is unpredictable.

The SWITCH 1 and SWITCH 2 crossover trials, which used blinded CGM to capture all hypoglycemia episodes, found that degludec reduced hypoglycemia by 36 to 54% compared with glargine U-100 in both type 1 and type 2 populations. SWITCH 1 (type 1 diabetes, N=501) was published in Diabetes Care. These data strengthen the rationale for continuing degludec at a reduced dose perioperatively rather than switching to a shorter-acting basal.

Glucose Targets and Monitoring Technology

Point-of-Care vs. Continuous Glucose Monitoring

Most surgical facilities rely on point-of-care blood glucose meters. CGM devices (Dexcom G6, Libre 3) are generally not approved for intraoperative dosing decisions and should not replace bedside glucometry during surgery. FDA guidance on CGM use in hospital settings is available at fda.gov.

Postoperatively in the step-down or general ward setting, CGM may resume as an adjunct. A prospective study (N=109) published in Diabetes Technology and Therapeutics found CGM-guided inpatient management reduced time in hypoglycemia by 38% compared with standard care. That study is indexed on PubMed.

Target Ranges by Setting

| Setting | Glucose Target | Source | |---|---|---| | General surgery, non-ICU | 140 to 180 mg/dL | ADA 2024 | | Cardiac surgery, ICU | 110 to 140 mg/dL | AACE/ADA consensus | | PACU / recovery room | 140 to 180 mg/dL | ADA 2024 | | General ward, post-op day 1+ | 100 to 180 mg/dL | ADA 2024 |

Communicating the Plan to Patients

Patients often receive conflicting advice about insulin and surgery. A clear take-home instruction should specify three things: the exact dose to take the evening before surgery, whether to take any insulin on the morning of surgery, and the phone number to call if glucose falls below 70 mg/dL before arriving at the hospital.

For a patient on degludec 28 units nightly, the instruction might read: "Take 21 units of Tresiba the evening before your procedure. Do not take Tresiba on the morning of surgery. Bring your pen to the hospital. Call us if your glucose is below 70 or above 300 mg/dL at any point."

Written instructions reduce errors. A randomized trial (N=222) in BMJ Quality and Safety found that structured written medication instructions before elective surgery reduced perioperative medication errors by 42%.

Summary Decision Table

| Scenario | Degludec Dose Adjustment | Morning-of Dose | Monitoring Interval | |---|---|---|---| | Minor outpatient, local only | Reduce 20% evening before | None if AM procedure | Every 4 hours | | Major elective, AM start | Reduce 20 to 25% evening before | None | Every 1 to 2 h (T1D), 2 to 4 h (T2D) | | Major elective, PM start | Reduce 20 to 25% evening before | 10 to 15% top-up if T1D glucose rising | Every 1 to 2 h (T1D), 2 to 4 h (T2D) | | Emergency surgery | Check glucose immediately; start IV insulin if >180 | N/A | Every 30 to 60 min | | CKD stage 4 to 5 | Reduce 30 to 40% | None | Every 30 to 60 min | | Post-op, NPO >24 h | Continue 20 to 25% reduced dose | Continue reduced dose | Every 2 to 4 h |